The invention provides novel nucleic acids and polypeptides, referred to
herein as stresscopin 1 and stresscopin 2, which preferentially activate
the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and
mimetics, and related CRH-R2 agonists suppress food intake and
heat-induced edema; but do not induce substantial release of ACTH.
Stresscopin also finds use in the recovery phase of stress responses, as
an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective
agent, and in the treatment of psychiatric and anxiolytic disorders.
Stresscopin nucleic acid compositions find use in identifying homologous
or related proteins and the DNA sequences encoding such proteins; in
producing compositions that modulate the expression or function of the
protein; and in studying associated physiological pathways.